Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299808 | 0.81 | CA1 (0.52) | HPGDTSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17749717 | 0.81 | KMT2A (0.42) | HPGDSMN1; SMN2HDAC2HDAC8HDAC6 | |
| SCHEMBL2928282 | 0.79 | CA1 (0.50) | TSHRHTTSMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL160742 | 0.79 | MAPT (0.42) | HPGDHTTSMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL2747933 | 0.79 | NPC1 (0.53) | TSHRSMN1; SMN2HDAC2HDAC8HDAC6 | |
| SCHEMBL17749739 | 0.79 | MMP13 (0.49) | HPGDHTTSMN1; SMN2MMP13ALDH1A1 | |
| SCHEMBL19640304 | 0.79 | KDM4E (0.47) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1303876 | 0.78 | PARP10 (0.52) | TSHRHTTALDH1A1CA2CYP1A2 | |
| SCHEMBL11199222 | 0.78 | RAB9A (0.61) | HPGDTSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17749754 | 0.78 | MLYCD (0.52) | HPGDSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC. (US) | 2020-02-11 | — | — | US | claimed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | claimed |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-16 | — | — | US | claimed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | claimed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| JP-2006516145-A | — | — | 2006-06-22 | — | — | JP | claimed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| CN-116003409-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | PFIZER INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005060665-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PLK1 4078/4885HPGD 2786/4885TSHR 332/4885 |
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | GABRB1, GABBR1, GABBR2 | PLK1 3082/4885HPGD 1416/4885TSHR 318/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | PLK1 3942/4885HPGD 2545/4885TSHR 336/4885 |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | CCR2, CCR5, CXCR3 | PLK1 3869/4885HPGD 3454/4885TSHR 182/4885 |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | GABRB1, GABBR1, GABBR2 | PLK1 3082/4885HPGD 1416/4885TSHR 318/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PLK1 4078/4885HPGD 2786/4885TSHR 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.